Roche (OTCQX:RHHBY) (OTCQX:RHHBF) has received the U.S. FDA’s approval for a subcutaneous version of its cancer immunotherapy, Tecentriq, developed using Halozyme Therapeutics’ (NASDAQ:HALO) Enhanze ...
Source LinkRoche (OTCQX:RHHBY) (OTCQX:RHHBF) has received the U.S. FDA’s approval for a subcutaneous version of its cancer immunotherapy, Tecentriq, developed using Halozyme Therapeutics’ (NASDAQ:HALO) Enhanze ...
Source Link
Comments